
Objective:To observe the efficacy and safety of vitrectomy combined with subretinal injection of alteplase (tPA) and intravitreal injection of Conbercept in the treatment of large area submacular hemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV).Methods:A retrospective clinical study. From January to September 2021, 32 eyes of 32 patients with massive SMH secondary to PCV diagnosed in the Affiliated Eye Hospital of Nanchang University were included in the study. Large SMH was defined as hemorrhage diameter ≥4 optic disc diameter (DD). There were 32 patients (32 eyes), 20 males and 12 females. The mean age was (72.36±8.62) years. All patients had unilateral disease.The duration from onset of symptoms to treatment was (7.21±3.36) days. All patients underwent best corrected visual acuity (BCVA) and optical coherence tomography (OCT) examination. BCVA examination was performed using the international standard visual acuity chart, which was converted to the logarithm of the minimum angle of resolution (logMAR) visual acuity during statistics. The central macular thickness (CMT) was measured by spectral domain-OCT. The average size of SMH was (6.82±1.53) DD. The logMAR BCVA 1.73±0.44; CMT was (727.96±236.40) μm. All patients were treated with 23G pars plana vitrectomy combined with subretinal injection of tPA and intravitreal injection of Conbercept. At 1, 3, 6 and 12 months after treatment, the same equipment and methods were used for relevant examinations before treatment. The changes of BCVA and CMT, the clearance rate of macular hemorrhage, and the complications during and after surgery were observed. BCVA and CMT before and after treatment were compared by repeated measures analysis of variance.Results:Compared with before treatment, BCVA gradually increased at 1, 3, 6 and 12 months after treatment, and the differences were statistically significant ( F=77.402, P<0.001). There was no significant difference in BCVA between any two groups at different time points after treatment ( P>0.05). Correlation analysis showed that BCVA at 12 months after treatment was negatively correlated with the course of disease ( r=-0.053, P=0.774). One week after treatment, macular hemorrhage was completely cleared in 30 eyes (93.75%, 30/32). The CMT was (458.56±246.21), (356.18±261.46), (345.82±212.38) and (334.64±165.54) μm at 1, 3, 6 and 12 months after treatment, respectively. Compared with before treatment, CMT decreased gradually after treatment, and the difference was statistically significant ( F=112.480, P<0.001). There were statistically significant differences in different follow-up time before and after treatment ( P<0.001). The number of treatments combined with Conbercept during and after surgery was (4.2±1.8) times. At the last follow-up, there was no recurrence of SMH, retinal interlamellar effusion and other complications. Conclusion:Subretinal injection of tPA combined with intravitreal injection of Conbercept is safe and effective in the treatment of large SMH secondary to PCV, and it can significantly improve the visual acuity of patients.
AIM: To observe and quantitatively analyze the thickness of macular ganglion cell inner plexiform layer(GCIPL)and the characteristics of superficial retinal capillaries vessel density in different stages of diabetic retinopathy(DR)by optical coherence tomography(OCT)and optical coherence tomography angiography(OCTA).METHODS: A retrospective case-control study. Thirty-three patients with diabetic(54 eyes)were selected as the DR group from December 2019 to May 2020. Among them, six patients(8 eyes)as non-diabetic retinopathy(NDR)group, eighteen patients(28 eyes)as non-proliferative diabetic retinopathy(NPDR)group and nine patients(18 eyes)as proliferative diabetic retinopathy(PDR)group according to fundus conditions. Eighteen healthy volunteers(26 eyes)without eye disease were selected as the normal group. The macular GCIPL thickness and the values of vascular linear density(vascular density, VD)and density of vascular perfusion(perfusion density, PD)in the superficial retinal capillaries vessels in each quadrant of macular region were observed and quantitatively analyzed in DR patients with different stages. RESULTS: The VD, PD and minimum thickness of GCIPL in each quadrant of DR group was lower than that of the healthy control group(P<0.05). The minimum thickness of GCIPL in macular area and the VD of superficial retinal capillaries in each quadrant decreased significantly in patients with different stages of diabetic retinopathy(P<0.01). The inferior VD of superficial retinal capillaries vessels had the highest diagnostic value for DR(AUC=0.807, optimal diagnostic threshold value of 18.60 mm-1, sensitivity of 0.923, specificity of 0.648). The minimum thickness of GCIPL in macular area of DR patients was positively correlated with VD of superficial retinal capillaries vessels in each quadrant(r=0.342, 0.480, 0.384, 0.342, all P<0.05). CONCLUSION: OCT combined with OCTA can provide repeatable and quantifiable detection methods and monitoring indicators for early assessment and regular follow-up of DR progress.
Objective To observe the clinical manifestations of a Wagner syndrome(WS)family.Methods A retrospective clinical study.Four patients(the proband,his father,sister,and brother)and one family member(the proband's mother)from a WS family diagnosed by clinical examination in Chengdu Aidi Eye Hospital in June 2023 were included in the study.The proband's medical history was examined in detail,followed by best corrected visual acuity(BCVA),fundus color photography,optical coherence tomography(OCT),and OCT angiography(OCTA).The proband underwent full field electroretinogram(ERG)examination.The proband and his sister and brother underwent blood glucose,blood pressure,hearing,face,joint,exercise and general physical examination at the same time.Peripheral venous blood was collected from the proband and 4 other family members.The proband extracts genomic DNA samples,conducts target region capture,library construction and high-throughput sequencing after qualified quality control.The suspected pathogenic mutation sites were verified by Sanger.According to the selected mutation sites,other family members in this family were co-isolated and verified.The pathogenicity of the mutation site was analyzed using the guidelines of the American College of Medical Genetics and Genomics(ACMG).Results Proband(Ⅱ-1)was 23 years old female.Both eyes BCVA were 0.1.The waveforms of ERG in both eyes were basically normal,and some amplitudes were reduced.Sister of the proband(Ⅱ-2)was 20 years old.Both eyes BCVA 1.0.Fundus examination showed no obvious abnormality.Brother of the proband(Ⅱ-3)was 19 years old.The left eye underwent pars plana vitrectomy combined with silicone oil filling 2 years ago due to retinal detachment and severe vitreous hyperplasia.BCVA light sensitivity,complicated cataract,and fundus opacity were observed.Right eye BCVA was 0.1.The lenses of the proband and his younger sister and brother were pointed and wedged,and the younger brother was heavier.Vitreous cavity of lens.The retina color of both eyes and the right eye of the younger brother of the protor was dark,with flaky dark areas on the side of the nose and the posterior pole,and the symmetrical retinal veil membrane hyperplasia and pulling on the periphery,showing small retinal splits.The choroidal retina showed focal and segmental symmetrically large atrophy.The optic disc was tilted.By OCT examination,the ellipsoid band was partially missing and broken,and the thickness of the choroid layer was reduced.Retinal cortical atrophy in 1 eye(younger brother of proband).By OCTA examination,the mesovascular layer of choroid was atrophied seriously and the blood density decreased.The results of laboratory and general examination of the three siblings showed no obvious abnormalities.The results of genetic testing showed that the proband,his father(Ⅱ-1),his sister and his brother carried a heterozygous mutation of the VCAN gene c.9264A>G(p.Pro3088=).According to ACMG guidelines,the pathogenicity of this variant was unknown.The mother of proband(Ⅰ-2)was wild type.Conclusions The abnormal manifestations of WS eyes are diverse,and both anterior and posterior segments could be involved.The pathogenicity of the heterozygous variation of VCAN gene c.9264A>G(P.RO3088=)in this family is unknown.
Age-related macular degeneration (AMD) is the main cause of low vision and even blindness in the elderly. With the aging of our population, the number of AMD patients will continue to rise. In the past decade, the rapid development of ocular fundus imaging technology has provided a new perspective and approach for the classification, diagnosis and follow-up of AMD. The advent of new drugs has provided more diverse intervention and treatment methods for AMD, especially for neovascular AMD, and the emphasis on accurate and individualized treatment has put forward higher requirements for retinal specialists. Therefore, based on the latest evidence-based medical information, combined with the international guidelines and the current situation of China′s social and economic development, experts from the Chinese Vitreo-Retinal Society of Chinese Medical Association, the Fundus Disease Group of Chinese Ophthalmologist Association, and the National Clinical Research Center for Eye Diseases gave recommendations around eight clinical problems and formed China′s guidelines for the clinical diagnosis and treatment of AMD. With the implementation of these guidelines, we can standardize the diagnosis, treatment, prevention and follow-up of AMD in China. (This article was published ahead of print on the official website of Chinese Journal of Ophthalmology on April 6, 2023)
外周渗出性出血性脉络膜视网膜病变(PEHCR)是以视网膜下出血和(或)视网膜色素上皮下出血或渗出为主要特征的周边视网膜疾病,常被误诊为老年性黄斑变性、息肉样脉络膜血管病变或脉络膜黑色素瘤等.随着多模式影像学发展,PEHCR在B型超声、荧光素眼底血管造影、光相干断层扫描等检查中表现出不同特征,据此可与上述疾病鉴别.该病治疗方法包括激光光凝治疗、玻璃体腔注射抗血管内皮生长因子药物和玻璃体切割手术等,但目前尚无统一治疗标准.未来仍需进一步深入了解PEHCR临床特征、治疗方案及预后,最大程度避免临床漏诊与误诊,提高治疗效率.